Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients : a descriptive analysis of the Eurobact II study
© 2022. The Author(s)..
BACKGROUND: The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 and non-COVID-19 critically ill patients.
METHODS: We used data from the Eurobact II study, a prospective observational multicontinental cohort study on HABSI treated in ICU. For the current analysis, we selected centers that included both COVID-19 and non-COVID-19 critically ill patients. We performed descriptive statistics between COVID-19 and non-COVID-19 in terms of patients' characteristics, source of infection and microorganism distribution. We studied the association between COVID-19 status and mortality using multivariable fragility Cox models.
RESULTS: A total of 53 centers from 19 countries over the 5 continents were eligible. Overall, 829 patients (median age 65 years [IQR 55; 74]; male, n = 538 [64.9%]) were treated for a HABSI. Included patients comprised 252 (30.4%) COVID-19 and 577 (69.6%) non-COVID-19 patients. The time interval between hospital admission and HABSI was similar between both groups. Respiratory sources (40.1 vs. 26.0%, p < 0.0001) and primary HABSI (25.4% vs. 17.2%, p = 0.006) were more frequent in COVID-19 patients. COVID-19 patients had more often enterococcal (20.5% vs. 9%) and Acinetobacter spp. (18.8% vs. 13.6%) HABSIs. Bacteremic COVID-19 patients had an increased mortality hazard ratio (HR) versus non-COVID-19 patients (HR 1.91, 95% CI 1.49-2.45).
CONCLUSIONS: We showed that the epidemiology of HABSI differed between COVID-19 and non-COVID-19 patients. Enterococcal HABSI predominated in COVID-19 patients. COVID-19 patients with HABSI had elevated risk of mortality. Trial registration ClinicalTrials.org number NCT03937245 . Registered 3 May 2019.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Critical care (London, England) - 26(2022), 1 vom: 18. Okt., Seite 319 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Buetti, Niccolò [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bacteremia |
|---|
| Anmerkungen: |
Date Completed 27.10.2022 Date Revised 28.10.2022 published: Electronic ClinicalTrials.gov: NCT03937245 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13054-022-04166-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347730035 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347730035 | ||
| 003 | DE-627 | ||
| 005 | 20231226034530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13054-022-04166-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347730035 | ||
| 035 | |a (NLM)36258239 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Buetti, Niccolò |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients |b a descriptive analysis of the Eurobact II study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2022 | ||
| 500 | |a Date Revised 28.10.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03937245 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 and non-COVID-19 critically ill patients | ||
| 520 | |a METHODS: We used data from the Eurobact II study, a prospective observational multicontinental cohort study on HABSI treated in ICU. For the current analysis, we selected centers that included both COVID-19 and non-COVID-19 critically ill patients. We performed descriptive statistics between COVID-19 and non-COVID-19 in terms of patients' characteristics, source of infection and microorganism distribution. We studied the association between COVID-19 status and mortality using multivariable fragility Cox models | ||
| 520 | |a RESULTS: A total of 53 centers from 19 countries over the 5 continents were eligible. Overall, 829 patients (median age 65 years [IQR 55; 74]; male, n = 538 [64.9%]) were treated for a HABSI. Included patients comprised 252 (30.4%) COVID-19 and 577 (69.6%) non-COVID-19 patients. The time interval between hospital admission and HABSI was similar between both groups. Respiratory sources (40.1 vs. 26.0%, p < 0.0001) and primary HABSI (25.4% vs. 17.2%, p = 0.006) were more frequent in COVID-19 patients. COVID-19 patients had more often enterococcal (20.5% vs. 9%) and Acinetobacter spp. (18.8% vs. 13.6%) HABSIs. Bacteremic COVID-19 patients had an increased mortality hazard ratio (HR) versus non-COVID-19 patients (HR 1.91, 95% CI 1.49-2.45) | ||
| 520 | |a CONCLUSIONS: We showed that the epidemiology of HABSI differed between COVID-19 and non-COVID-19 patients. Enterococcal HABSI predominated in COVID-19 patients. COVID-19 patients with HABSI had elevated risk of mortality. Trial registration ClinicalTrials.org number NCT03937245 . Registered 3 May 2019 | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bacteremia | |
| 650 | 4 | |a Bloodstream infection | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Enterococcus | |
| 650 | 4 | |a ICU-acquired | |
| 700 | 1 | |a Tabah, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Loiodice, Ambre |e verfasserin |4 aut | |
| 700 | 1 | |a Ruckly, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Aslan, Abdullah Tarik |e verfasserin |4 aut | |
| 700 | 1 | |a Montrucchio, Giorgia |e verfasserin |4 aut | |
| 700 | 1 | |a Cortegiani, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Saltoglu, Nese |e verfasserin |4 aut | |
| 700 | 1 | |a Kayaaslan, Bircan |e verfasserin |4 aut | |
| 700 | 1 | |a Aksoy, Firdevs |e verfasserin |4 aut | |
| 700 | 1 | |a Murat, Akova |e verfasserin |4 aut | |
| 700 | 1 | |a Akdoğan, Özlem |e verfasserin |4 aut | |
| 700 | 1 | |a Saracoglu, Kemal Tolga |e verfasserin |4 aut | |
| 700 | 1 | |a Erdogan, Cem |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer, Ricard |e verfasserin |4 aut | |
| 700 | 1 | |a Paiva, José-Artur |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Yoshiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ramanan, Mahesh |e verfasserin |4 aut | |
| 700 | 1 | |a Conway Morris, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Barbier, François |e verfasserin |4 aut | |
| 700 | 1 | |a Timsit, Jean-François |e verfasserin |4 aut | |
| 700 | 0 | |a Eurobact 2 study group |e verfasserin |4 aut | |
| 700 | 1 | |a Lipman, Jeffrey |e investigator |4 oth | |
| 700 | 1 | |a Litton, Edward |e investigator |4 oth | |
| 700 | 1 | |a Palermo, Anna Maria |e investigator |4 oth | |
| 700 | 1 | |a Yap, Timothy |e investigator |4 oth | |
| 700 | 1 | |a Eroglu, Ege |e investigator |4 oth | |
| 700 | 1 | |a Hosokawa, Koji |e investigator |4 oth | |
| 700 | 1 | |a Yoshida, Hideki |e investigator |4 oth | |
| 700 | 1 | |a Fujitani, Shigeki |e investigator |4 oth | |
| 700 | 1 | |a Zand, Farid |e investigator |4 oth | |
| 700 | 1 | |a Mahmoodpoor, Ata |e investigator |4 oth | |
| 700 | 1 | |a Tabatabaei, Seyed Mohammad Nasirodin |e investigator |4 oth | |
| 700 | 1 | |a Elrabi, Omar |e investigator |4 oth | |
| 700 | 1 | |a Almekhlafi, Ghaleb A |e investigator |4 oth | |
| 700 | 1 | |a Vidal, Gabriela |e investigator |4 oth | |
| 700 | 1 | |a Aparicio, Marta |e investigator |4 oth | |
| 700 | 1 | |a Alonzo, Irene |e investigator |4 oth | |
| 700 | 1 | |a Namendys-Silva, Silvio A |e investigator |4 oth | |
| 700 | 1 | |a Hermosillo, Mariana |e investigator |4 oth | |
| 700 | 1 | |a Castillo, Roberto Alejandro |e investigator |4 oth | |
| 700 | 1 | |a De Bus, Liesbet |e investigator |4 oth | |
| 700 | 1 | |a De Waele, Jan |e investigator |4 oth | |
| 700 | 1 | |a Hollevoet, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a De Schryver, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Serck, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Kovacevic, Pedja |e investigator |4 oth | |
| 700 | 1 | |a Zlojutro, Biljana |e investigator |4 oth | |
| 700 | 1 | |a Ruppe, Etienne |e investigator |4 oth | |
| 700 | 1 | |a Montravers, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Dulac, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Castanera, Jérémy |e investigator |4 oth | |
| 700 | 1 | |a Massri, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Guesdon, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Garcon, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Duprey, Matthieu |e investigator |4 oth | |
| 700 | 1 | |a Philippart, François |e investigator |4 oth | |
| 700 | 1 | |a Tran, Marc |e investigator |4 oth | |
| 700 | 1 | |a Bruel, Cédric |e investigator |4 oth | |
| 700 | 1 | |a Kalfon, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Badre, Gaëtan |e investigator |4 oth | |
| 700 | 1 | |a Demeret, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Le Guennec, Loïc |e investigator |4 oth | |
| 700 | 1 | |a Bassetti, Matteo |e investigator |4 oth | |
| 700 | 1 | |a Giacobbe, Daniele |e investigator |4 oth | |
| 700 | 1 | |a Sales, Gabriele |e investigator |4 oth | |
| 700 | 1 | |a Daroui, Ivan |e investigator |4 oth | |
| 700 | 1 | |a Lodi, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Ippolito, Mariachiara |e investigator |4 oth | |
| 700 | 1 | |a Bellina, Davide |e investigator |4 oth | |
| 700 | 1 | |a Di Guardo, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Rocco, Monica |e investigator |4 oth | |
| 700 | 1 | |a Fiorelli, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Mikstacki, Adam |e investigator |4 oth | |
| 700 | 1 | |a Peichota, Mariusz |e investigator |4 oth | |
| 700 | 1 | |a Pietraszek-Grzywaczewska, Iwona |e investigator |4 oth | |
| 700 | 1 | |a Póvoa, Pedro |e investigator |4 oth | |
| 700 | 1 | |a Krystopchuk, Andriy |e investigator |4 oth | |
| 700 | 1 | |a Teresa, Ana |e investigator |4 oth | |
| 700 | 1 | |a de Figueiredo, António Manuel Pereira |e investigator |4 oth | |
| 700 | 1 | |a Botelho, Isabel |e investigator |4 oth | |
| 700 | 1 | |a Costa, Vasco |e investigator |4 oth | |
| 700 | 1 | |a Cunha, Rui Pedro |e investigator |4 oth | |
| 700 | 1 | |a Gritsan, Alexey |e investigator |4 oth | |
| 700 | 1 | |a Belskiy, Vladislav |e investigator |4 oth | |
| 700 | 1 | |a Furman, Mikhail |e investigator |4 oth | |
| 700 | 1 | |a Martinez, Maria |e investigator |4 oth | |
| 700 | 1 | |a Casares, Vanessa |e investigator |4 oth | |
| 700 | 1 | |a Arnillas, Maria Pilar Gracia |e investigator |4 oth | |
| 700 | 1 | |a Bermudez, Rosana Munoz |e investigator |4 oth | |
| 700 | 1 | |a Ubeda, Alejandro |e investigator |4 oth | |
| 700 | 1 | |a Salgado, Maria |e investigator |4 oth | |
| 700 | 1 | |a Maseda, Emilio |e investigator |4 oth | |
| 700 | 1 | |a De La Rica, Alejandro Suarez |e investigator |4 oth | |
| 700 | 1 | |a Blasco-Navalpotro, Miguel Angel |e investigator |4 oth | |
| 700 | 1 | |a Gallego, Alberto Orejas |e investigator |4 oth | |
| 700 | 1 | |a Prazak, Josef |e investigator |4 oth | |
| 700 | 1 | |a Pagani, J L |e investigator |4 oth | |
| 700 | 1 | |a Abed-Maillard, S |e investigator |4 oth | |
| 700 | 1 | |a Iskit, Arzu Topeli |e investigator |4 oth | |
| 700 | 1 | |a Mehtap, Selcuk |e investigator |4 oth | |
| 700 | 1 | |a Ceyhun, Solakoğlu |e investigator |4 oth | |
| 700 | 1 | |a Kalem, Ayşe Kaya |e investigator |4 oth | |
| 700 | 1 | |a Kurt, Ibrahim |e investigator |4 oth | |
| 700 | 1 | |a Telli, Murat |e investigator |4 oth | |
| 700 | 1 | |a Ozturk, Barcin |e investigator |4 oth | |
| 700 | 1 | |a Baykam, Nurcan |e investigator |4 oth | |
| 700 | 1 | |a Karaali, Ridvan |e investigator |4 oth | |
| 700 | 1 | |a Koksal, Iftihar |e investigator |4 oth | |
| 700 | 1 | |a Bilir, Yeliz |e investigator |4 oth | |
| 700 | 1 | |a Guzeldag, Seda |e investigator |4 oth | |
| 700 | 1 | |a Ersoz, Gulden |e investigator |4 oth | |
| 700 | 1 | |a Evik, Guliz |e investigator |4 oth | |
| 700 | 1 | |a Bayindir, Yasar |e investigator |4 oth | |
| 700 | 1 | |a Ersoy, Yasemin |e investigator |4 oth | |
| 700 | 1 | |a Ercole, Ari |e investigator |4 oth | |
| 700 | 1 | |a Raj, Ashok |e investigator |4 oth | |
| 700 | 1 | |a Zormpa, Artemis |e investigator |4 oth | |
| 700 | 1 | |a Tinaslanidis, George |e investigator |4 oth | |
| 700 | 1 | |a Khade, Reena |e investigator |4 oth | |
| 700 | 1 | |a Roshdy, Ashraf |e investigator |4 oth | |
| 700 | 1 | |a Kannan, Santhana |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Critical care (London, England) |d 1997 |g 26(2022), 1 vom: 18. Okt., Seite 319 |w (DE-627)NLM097399787 |x 1466-609X |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:1 |g day:18 |g month:10 |g pages:319 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13054-022-04166-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 1 |b 18 |c 10 |h 319 | ||